Endocrine Abstracts

Purpose: Methimazole (MMI) is a widely used antithyroid agent for first-line treatment of hyperthyroidism. A warning has been recently issued by the European Medicine Agency (EMA) regarding a potential increased risk of acute pancreatitis (AP) in MMI users, based on evidences from published case reports and post-marketing surveillance. The aim of this study was to investigate the association between MMI treatment and the diagnosis of AP in drug users.Mat...

Introduction: Neuroendocrine neoplasms are rare and multiform requiring a multidisciplinary approach. We report the experience of a Neuroendocrine tumor board (TB) established at our University Hospital.Aims: The aim is to share clinical and diagnostic data for best decision-making according to the existing ENETS guidelines.Materials and methods: According to the indications for ENETS Centers of Excellence, meetings with experts in...

RT-coding genes are expressed at very low levels in differentiated, non pathological tissues, while are significantly up-regulated in undifferentiated and transformed cells, suggesting a direct correlation between the level of expression of RT and the proliferative state of the cell. Either nevirapine and efavirenz, two RT inhibitors, used in the therapy of AIDS, reversibly down-regulate cell proliferation and induce differentiation in several human tumor cell lines.<p cla...

Background and aim: Information on incidence and prevalence of acromegaly usually originates from studies performed in referral endocrine care centers, whose catchment areas do not generally cover the entire population. Administrative databases can provide key information to assess the impact of acromegaly on patients and health systems. Our study aimed at estimating the prevalence and incidence data of acromegaly stratified by age and sex using data obtained in the Piedmont r...

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...